These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3825737)

  • 1. GABA-dopamine relationship in Parkinson's disease striatum.
    Kish S; Rajput A; Gilbert J; Rozdilsky B; Chang LJ; Shannak K; Hornykiewicz O
    Adv Neurol; 1987; 45():75-7. PubMed ID: 3825737
    [No Abstract]   [Full Text] [Related]  

  • 2. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss.
    Kish SJ; Rajput A; Gilbert J; Rozdilsky B; Chang LJ; Shannak K; Hornykiewicz O
    Ann Neurol; 1986 Jul; 20(1):26-31. PubMed ID: 2874765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corpus striatum in paralysis agitans and in perphenazine-injected rats.
    Pakkenberg H; Bottcher J
    Adv Neurol; 1974; 5():203-9. PubMed ID: 4440571
    [No Abstract]   [Full Text] [Related]  

  • 5. Positron emission tomography of striatal serotonin transporters in Parkinson disease.
    Kerenyi L; Ricaurte GA; Schretlen DJ; McCann U; Varga J; Mathews WB; Ravert HT; Dannals RF; Hilton J; Wong DF; Szabo Z
    Arch Neurol; 2003 Sep; 60(9):1223-9. PubMed ID: 12975287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal dopaminergic neurons are lost with Parkinson's disease progression.
    Porritt MJ; Kingsbury AE; Hughes AJ; Howells DW
    Mov Disord; 2006 Dec; 21(12):2208-11. PubMed ID: 17029264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopaminergic innervation of the human striatum in Parkinson's disease.
    Papapetropoulos S; Basel M; Mash DC
    Mov Disord; 2007 Jan; 22(2):286-8. PubMed ID: 17083095
    [No Abstract]   [Full Text] [Related]  

  • 8. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
    Murray AM; Weihmueller FB; Marshall JF; Hurtig HI; Gottleib GL; Joyce JN
    Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal extracts from patients with Parkinson's disease promote dopamine neuron growth in mesencephalic cultures.
    Carvey PM; Ptak LR; Nath ST; Sierens DK; Mufson EJ; Goetz CG; Klawans HL
    Exp Neurol; 1993 Mar; 120(1):149-52. PubMed ID: 8097475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Morphologic aspects of the function of the neostriatum].
    Danner H; Pfister C
    Psychiatr Neurol Med Psychol Beih; 1983; 29():29-35. PubMed ID: 6314414
    [No Abstract]   [Full Text] [Related]  

  • 11. Mechanisms of neuronal loss in Parkinson's disease: a neuroanatomical-biochemical perspective.
    Hornykiewicz O
    Clin Neurol Neurosurg; 1992; 94 Suppl():S9-11. PubMed ID: 1320533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrastructural chemoanatomy of the basal ganglia: an overview.
    Pasik P; Pasik T; Holstein GR
    Adv Neurol; 1987; 45():59-66. PubMed ID: 2881451
    [No Abstract]   [Full Text] [Related]  

  • 13. Diorthosubstituted polychlorinated biphenyls in caudate nucleus in Parkinson's disease.
    Corrigan FM; Murray L; Wyatt CL; Shore RF
    Exp Neurol; 1998 Apr; 150(2):339-42. PubMed ID: 9527905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
    Kish SJ; Tong J; Hornykiewicz O; Rajput A; Chang LJ; Guttman M; Furukawa Y
    Brain; 2008 Jan; 131(Pt 1):120-31. PubMed ID: 17956909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The susceptibility to acetylcholine and dopamine in the caudate nucleus of cats with chronic nigrostriatal lesions.
    Sphelmann R
    Trans Am Neurol Assoc; 1974; 99():255-7. PubMed ID: 4156892
    [No Abstract]   [Full Text] [Related]  

  • 16. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease.
    Ryoo HL; Pierrotti D; Joyce JN
    Mov Disord; 1998 Sep; 13(5):788-97. PubMed ID: 9756147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early-stage loss of dopamine uptake-site binding in MPTP-treated monkeys.
    Graybiel AM; Moratalla R; Quinn B; DeLanney LE; Irwin I; Langston JW
    Adv Neurol; 1993; 60():34-9. PubMed ID: 8420148
    [No Abstract]   [Full Text] [Related]  

  • 18. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.
    Mogi M; Kondo T; Mizuno Y; Nagatsu T
    Neurosci Lett; 2007 Feb; 414(1):94-7. PubMed ID: 17196747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of aging on the interaction between glutamate, dopamine, and GABA in striatum and nucleus accumbens of the awake rat.
    Segovia G; Del Arco A; Mora F
    J Neurochem; 1999 Nov; 73(5):2063-72. PubMed ID: 10537066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence of a breakdown of corticostriatal connections in Parkinson's disease.
    Stephens B; Mueller AJ; Shering AF; Hood SH; Taggart P; Arbuthnott GW; Bell JE; Kilford L; Kingsbury AE; Daniel SE; Ingham CA
    Neuroscience; 2005; 132(3):741-54. PubMed ID: 15837135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.